HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q3 2015 13F Holders as of 30 Sep 2015

Type / Class
Equity / COM
Total 13F shares
3,731,369
Share change
+35,793
Total reported value
$28,435,000
Price per share
$7.62
Number of holders
20
Value change
-$227,047
Number of buys
8
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q3 2015

As of 30 Sep 2015, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 20 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,731,369 shares. The largest 10 holders included Novo A/S, FMR LLC, PUTNAM INVESTMENTS LLC, BlackRock Advisors LLC, Cormorant Asset Management, LLC, BlackRock Group LTD, Alyeska Investment Group, L.P., VANGUARD GROUP INC, BlackRock Investment Management, LLC, and MACKENZIE FINANCIAL CORP. This page lists 20 institutional shareholders reporting positions in this security for the Q3 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.